NSE filing, NSE: BAJAJHCARE. Summary written from the filing by ALFA Finder's alert engine.
Bajaj Healthcare Ltd: key numbers
- Share price
- ₹314.45
- Market cap
- ₹1,059 Cr
- Revenue (annual)
- ₹611.0 Cr
- Net profit (annual)
- ₹15.77 Cr
- P/E (TTM)
- 51.4×Sector 46.1×
- Promoter holding
- 58.59%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bajaj Healthcare Ltd
All →Bajaj Healthcare Earnings Call Transcript: Key Takeaways
Bajaj Healthcare delivered strong H1 growth led by a 82% surge in formulations and key new specialty launches.
- Call
- Guides 15% growth
Bajaj Healthcare Results Update
Bajaj Healthcare reported Q2 FY27 revenue of ₹175.9 Crore, up 18.9% YoY. EBITDA stood at ₹32.1 Crore, reflecting a 12.2% YoY increase.
Bajaj Healthcare Other Announcement
Bajaj Healthcare filed its Monitoring Agency Report for the quarter ended September 30, 2026, as required by SEBI regulations for the utilization of preferential issue proceeds.
Bajaj Healthcare Q2 FY27 Results: Net Profit ₹14.1 Cr, Up 27.0% YoY
Bajaj Healthcare Ltd reported revenue from operations of ₹175.9 Cr (+18.9% YoY) and net profit of ₹14.1 Cr (+27.0% YoY) for Q2 FY27.
- Key figure
- Net profit ₹14.1 Cr · +27.0% YoY
Bajaj Healthcare Acquisition
Bajaj Healthcare received NCLT approval to acquire Genrx Pharmaceuticals Private Limited as a going concern. The entity will become a wholly owned subsidiary.
Bajaj Healthcare Merger & Restructuring Worth ₹14.67 Cr
Bajaj Healthcare Limited has executed a deed of assignment to sell its undertaking located in Dahej Industrial Area, Gujarat, for approximately Rs. 14.67 Crore.
- Value
- ₹14.67 Cr
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.